- Telix Pharmaceuticals’ (TLX) first patient has been dosed with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC)
- TLX250-CDx is being developed by Telix for the purpose of determining whether “indeterminate renal masses” are either clear cell renal cell cancer or not
- The study is aligned with Telix’s focus on the development of alpha therapy in future pipeline expansion and its strategy to pursue additional indications for the CA9 target
- Two other studies evaluating CA9 have been initiated for bladder cancer, and triple negative breast cancer
- Telix Pharmaceuticals (TLX) last traded at $7.40 per share before market open on December 21
Telix Pharmaceuticals’ (TLX) first patient has been dosed with TLX250-CDx for non-muscle invasive bladder cancer (NMIBC).
TLX250-CDx is being developed by Telix for the purpose of determining whether “indeterminate renal masses” are either clear cell renal cell cancer (ccRCC) or non-ccRCC.
The objective of the study currently being done is to evaluate the safety, biodistribution and dosing properties of TLX250-CDx in patients with NMIBC.
The study builds on the Telix and ATONCO licence and development agreement and will be led by Dr Caroline Rousseau at the Institut de Cancérologie de l’Ouest in France.
The study will recruit 6 patients over 12 months, and with a successful outcome, it will move to therapeutic studies for targeted alpha therapy (TAT).
TLX250-CDx targets carbonic anhydrase IX (CA9), a receptor that is overexpressed in solid tumours.
The study is aligned with Telix’s focus on the development of alpha therapy in future pipeline expansion and its strategy to pursue additional indications for the CA9 target.
CA9 is currently being evaluated in clear cell renal cell carcinoma in Telix’s Phase II therapeutic studies and Phase III imaging study.
Phase I is investigating CA9 as a target for molecularly-targeted radiation (MTR) in other tumour types, as well as providing a pathway to evaluate TLX250 with an alpha-emitting isotope.
Alpha emitters have the potential to deliver very high amounts of energy to cancer tissue, whilst the short path length can decrease the risk of damage to surrounding healthy cells.
This increases the selectivity and potency of the radiation treatment.
Alpha emitters have the potential to be complementary to beta-emitters in different stages of the disease.
Two other studies evaluating CA9 have been initiated for bladder cancer, and triple-negative breast cancer.
It is also being done alongside other studies for development in ovarian, colorectal, head and neck, lung, and pancreatic cancers.
Telix Pharmaceuticals (TLX) last traded at $7.40 per share before the market opens on December 21.